The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®

The CD25-binding antibody daclizumab high-yield process (DAC HYP) is an interleukin (IL)-2 signal modulating antibody that shares primary amino acid sequence and CD25 binding affinity with Zenapax®, a distinct form of daclizumab, which was approved for the prevention of acute organ rejection in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganguly, Bishu, Balasa, Balaji, Efros, Lyubov, Hinton, Paul R., Hartman, Stephen, Thakur, Archana, Xiong, Joanna M., Schmidt, Brian, Robinson, Randy R., Sornasse, Thierry, Vexler, Vladimir, Sheridan, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058627/
https://www.ncbi.nlm.nih.gov/pubmed/27367933
http://dx.doi.org/10.1080/19420862.2016.1207031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058627/
https://www.ncbi.nlm.nih.gov/pubmed/27367933
http://dx.doi.org/10.1080/19420862.2016.1207031

Ejemplares similares